<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911122-0031</DOCNO><DOCID>911122-0031.</DOCID><HL>   Business Brief -- Medtronic Inc.:   Earnings in Second Period   Rose 34% on 9% Sales Rise</HL><DATE>11/22/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C17</SO><CO>   MDT</CO><MS>TECHNOLOGY (TEC)</MS><IN>EARNINGS (ERN)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>EARNINGS (ERN)</NS><RE>MINNESOTA (MN)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Medtronic Inc., Minneapolis, said fiscal second-quarterearnings rose 34% on a 9% rise in sales, reflecting anotherstrong performance by the company's U.S. pacemaker business.   For the quarter ended Oct. 31, the maker of biomedicaldevices earned $38.5 million, or 65 cents a share, on salesof $279 million. In the year-earlier quarter, Medtronic hadnet income of $28.7 million, or 48 cents a share, on sales of$254.6 million. Prior-year results include costs associatedwith the September 1990 acquisition of BioMedicus Inc.</LP><TEXT>   Medtronic said its performance reflects &quot;the strongacceptance of its products in the marketplace.&quot; The companysaid pacemaker unit sales rose 6.5% in the U.S., led by theMedtronic Elite dual chamber pacemaker, which was approved bythe Food and Drug Administration last April.   The company said world-wide sales rose 9.6%, but continuedto reflect negative effects of foreign exchange translation.   For the first half of fiscal 1992, Medtronic earnings rose27% to $74.7 million, or $1.25 a share, from $59 million, or$1 a share. Sales rose 11% to $543.7 million from $487.9million.</TEXT></DOC>